Apigenin: The Sleep and Longevity Ingredient Hiding in Chamomile

Apigenin is the plant flavone that gives chamomile its calming reputation. It binds the same receptor target as benzodiazepines (the GABA-A receptor) but acts far more gently, so it is associated with relaxation rather than heavy sedation. The strongest human sleep evidence comes from chamomile extract trials, where results are real but modest and mixed. Isolated apigenin has mostly been studied in cells and animals, including research linking it to NAD+ and aging. It is commonly used at around 50 mg, has a long history of safe dietary intake, and works best as one layer of a calming stack.

Apigenin has quietly become one of the most searched sleep ingredients of the last two years, helped along by longevity podcasts and a growing interest in compounds that touch both sleep and aging. A lot of what gets written about it online is either thin or overstated. This guide does the opposite. It walks through what apigenin actually is, how it works in the brain, what the human and preclinical evidence does and does not show, the longevity angle that made it famous, how it is dosed in real products, whether it is safe to take nightly, and where it fits alongside other calming ingredients. Every claim below is tied to a peer-reviewed source you can open and read yourself.

1. What apigenin is (and the chamomile connection)

Apigenin is a natural flavone (a type of plant flavonoid) found in chamomile, parsley, celery, and several other plants. It is the compound most often credited for chamomile tea's reputation as a bedtime drink. Chemically it is known as 4',5,7-trihydroxyflavone, and it is one of the active molecules concentrated in the dried flower heads of chamomile (Matricaria chamomilla, also written as Matricaria recutita).

The link to chamomile is not folklore. In 1995, researchers fractionating an aqueous chamomile extract isolated apigenin specifically because it was the fraction that bound a relaxation-related receptor in the brain. That study is the origin point for treating apigenin as the calming molecule inside chamomile.

Citation: Viola H, et al. Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects. Planta Medica, 1995. PubMed: 7617761

One honest detail that most articles skip: chamomile is a relatively dilute source of apigenin. Chamomile extracts typically yield only around one percent apigenin by weight, and a cup of chamomile tea delivers a small amount. This matters later, because it means the calming effects people associate with chamomile come from a modest apigenin dose alongside dozens of other plant compounds, not from a concentrated hit of the isolated molecule.

Citation: Kramer DJ, Johnson AA. Apigenin: a natural molecule at the intersection of sleep and aging. Frontiers in Nutrition, 2024. PubMed Central: PMC10929570

2. How apigenin works in the brain: the GABA-A story

Apigenin appears to calm the nervous system by acting at the benzodiazepine binding site of the GABA-A receptor, the same broad target that anti-anxiety and sleep medications use. The key difference is that apigenin binds gently. At normal doses it behaves more like a mild relaxant than a sedative.

GABA is the brain's main inhibitory neurotransmitter, the signal that quiets neural activity and helps the system wind down. The GABA-A receptor has a separate docking site (the benzodiazepine site) that other molecules can attach to in order to fine-tune how strongly GABA acts. In the 1995 chamomile study, apigenin competitively bound this site and displaced a benzodiazepine tracer, with a binding strength (Ki) of about 4 micromolar. In mice, it produced clear anti-anxiety behavior at doses comparable to classic benzodiazepines, but without the sedation or muscle relaxation those drugs cause. Only when the dose was raised roughly tenfold did a mild sedative effect appear.

Citation: Viola H, et al. Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects. Planta Medica, 1995. PubMed: 7617761

There is an important piece of nuance here that gets lost in most summaries. In that same study, apigenin did not change how the core GABA-binding part of the receptor behaved (it had no effect on muscimol binding), and it was not anticonvulsant or muscle-relaxing. So the accurate way to describe the mechanism is that apigenin is a gentle modulator at one specific site on the receptor, which fits its real-world profile of promoting calm without knocking you out. This is a plausible biological reason it could support the transition to sleep. It is not, on its own, proof that it improves sleep in humans. That question is answered by the clinical evidence in the next section.

3. What the sleep evidence actually shows

The honest summary is this: human sleep evidence for apigenin comes almost entirely from chamomile extract trials, and those results are real but modest and inconsistent. There are essentially no human trials of isolated apigenin for sleep. Most of the apigenin-specific sleep data is preclinical, meaning cells and animals. This is exactly where the gap between hype and proof sits, so it is worth walking through carefully.

Start with the best human signal. A 2024 systematic review and meta-analysis pooled ten chamomile sleep trials covering 772 participants. It found a statistically significant improvement in overall sleep quality, measured as a reduction in the Pittsburgh Sleep Quality Index. Sleep onset, the time it takes to fall asleep, improved in three of the four trials that measured it.

Citation: Kazemi A, et al. Effects of chamomile (Matricaria chamomilla L.) on sleep: A systematic review and meta-analysis of clinical trials. Complementary Therapies in Medicine, 2024. PubMed: 39106912

Now the caveats, because they are the point. That same meta-analysis reported very high statistical heterogeneity between studies, meaning the trials disagreed with each other a lot. Daytime functioning did not improve across the studies that measured it, and sleep efficiency was unchanged in two trials and slightly worse in one. So the fair reading is that chamomile nudges subjective sleep quality in the right direction, with the most consistent effect on how quickly people fall asleep, but it is not a dramatic or uniform result.

The most rigorous single trial makes the same point even more bluntly. A double-blind, placebo-controlled study gave 34 adults with chronic insomnia 270 mg of chamomile extract twice daily for 28 days. It found no statistically significant advantage over placebo on its main sleep diary measures, including total sleep time, sleep efficiency, time to fall asleep, and night awakenings. There were small to moderate effect sizes favoring chamomile on a few secondary measures, but the primary result was a miss.

Citation: Zick SM, et al. Preliminary examination of the efficacy and safety of a standardized chamomile extract for chronic primary insomnia: a randomized placebo-controlled pilot study. BMC Complementary and Alternative Medicine, 2011. PubMed: 21939549

On the other side, a randomized trial in older adults found that chamomile extract improved sleep quality compared with a control group, which is part of why chamomile keeps showing up as a gentle option for this population. The design and population here were less stringent than a tightly controlled insomnia trial, so it is supportive rather than definitive.

Citation: Abdullahzadeh M, et al. Investigation effect of oral chamomilla on sleep quality in elderly people in Isfahan: A randomized control trial. Journal of Education and Health Promotion, 2017. PubMed: 28616420

For isolated apigenin specifically, the sleep evidence is preclinical. Animal studies show that apigenin can induce sedative effects in mice and rats, which lines up with the GABA-A mechanism. The 2024 review that brought apigenin into the longevity conversation is clear that direct apigenin-only human sleep trials are missing, and that the clinical support leans on chamomile, which delivers apigenin in low amounts alongside other compounds. Anyone claiming apigenin is a proven human sleep aid is getting ahead of the data.

Citation: Kramer DJ, Johnson AA. Apigenin: a natural molecule at the intersection of sleep and aging. Frontiers in Nutrition, 2024. PubMed Central: PMC10929570

4. The longevity angle: CD38, NAD+, and what is and is not proven

Apigenin became a longevity talking point because it inhibits an enzyme called CD38, which is one of the main consumers of NAD+ in the body. NAD+ is a molecule central to cellular energy and repair that declines with age. The catch worth saying upfront is that the entire NAD+ and longevity story for apigenin sits in cells, mice, flies, and worms. No human trial has shown that apigenin supplements raise NAD+ or extend lifespan in people.

Here is the chain of logic, with the evidence attached to each link. First, apigenin is a CD38 inhibitor. A 2013 study characterized apigenin (and the related flavonoid quercetin) as inhibitors of CD38, showed that blocking CD38 raised intracellular NAD+ levels in cell cultures, and found that giving apigenin to obese mice increased NAD+ and improved aspects of their glucose and lipid metabolism.

Citation: Escande C, et al. Flavonoid apigenin is an inhibitor of the NAD+ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes, 2013. PubMed: 23172919

Second, the 2024 review tied this metabolic mechanism to the sleep and aging literature in one place, noting that in animal models apigenin both supported sleep-related behavior and produced longevity signals, such as longer survival in fly models of neurodegenerative disease and increased lifespan in worms given apigenin glycosides, along with better learning and memory in older mice. That is a genuinely interesting convergence of two research areas in one molecule.

Citation: Kramer DJ, Johnson AA. Apigenin: a natural molecule at the intersection of sleep and aging. Frontiers in Nutrition, 2024. PubMed Central: PMC10929570

Now the honest boundary. Everything above is mechanism and animal biology. The doses used to move NAD+ in animals are large relative to body weight and far above what a person gets from a sleep supplement. The leap from worms and obese mice to a human living longer or sleeping better because of NAD+ has not been tested in a human trial. The longevity framing is best understood as a plausible and well-studied hypothesis, not an established human benefit. That distinction is the whole reason this section exists.

5. Apigenin dosing in the real world (including Lunia's 50 mg)

There is no officially established or clinically proven apigenin dose for sleep in humans, because the human trials used chamomile extract rather than measured apigenin. In supplements, apigenin commonly appears at around 50 mg per serving, which is the amount used in Lunia Restore. Chamomile extract sleep trials used 200 mg to 1,500 mg of extract, which contains only a small fraction of that as apigenin.

To make this concrete, the chamomile insomnia trial used 540 mg of extract per day (270 mg twice), and the long-term chamomile trials used up to 1,500 mg of extract per day. Because chamomile yields only about one percent apigenin, even those larger extract doses delivered a relatively small amount of apigenin itself. A 50 mg dose of isolated apigenin is therefore in a sensible, widely used range for a calming sleep formula, and it is positioned as a supporting ingredient rather than a megadose meant to replicate animal experiments.

Citation: Mao JJ, et al. Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial. Phytomedicine, 2016. PubMed: 27912875

One more factor shapes dosing more than most labels admit: absorption. Apigenin taken by mouth has poor bioavailability. A large portion is either excreted unabsorbed or rapidly metabolized after absorption, and a meaningful fraction is processed by gut bacteria rather than entering the bloodstream intact. This is part of why simply taking more is not a reliable way to get more effect, and why apigenin is usually paired with ingredients that have stronger standalone human evidence rather than relied on by itself.

Citation: Tang D, et al. Pharmacokinetic properties and drug interactions of apigenin, a natural flavone. Expert Opinion on Drug Metabolism and Toxicology, 2017. DOI: 10.1080/17425255.2017.1251903

6. Is apigenin safe to take nightly?

Apigenin has a strong safety profile for general use. It is a common compound in everyday foods like celery, parsley, and chamomile, and it has been consumed for centuries with low reported toxicity. The longest human safety data comes from chamomile extract, which was well tolerated over many months. The main cautions are allergy, combining it with other sedatives, pregnancy, and certain medications.

The most reassuring human safety data sits in a study where adults took 1,500 mg of chamomile extract per day through an open-label phase and then continued for several more months in a controlled phase. Across roughly 38 weeks of treatment, adverse event rates were low and similar to placebo. That is a longer continuous safety window than most sleep supplements can point to.

Citation: Mao JJ, et al. Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial. Phytomedicine, 2016. PubMed: 27912875

The sensible cautions are straightforward. People with allergies to ragweed or other plants in the daisy (Asteraceae) family can react to chamomile, so chamomile-derived ingredients deserve care there. Because apigenin acts at a benzodiazepine-related site, it is reasonable to be conservative about stacking it with prescription sedatives, sleep medications, or alcohol. Chamomile contains natural coumarins, so anyone on blood-thinning medication should check with a clinician first. And because there is not enough data in pregnancy and breastfeeding, the cautious default is to avoid it then. None of this is medical advice, and anyone with a health condition or on medication should talk to their own clinician before starting any supplement.

7. Where apigenin fits in a sleep stack

Apigenin works best as one calming layer in a stack rather than a standalone sleep aid. Its gentle GABA-A activity complements two ingredients with stronger standalone human evidence: magnesium and L-theanine. Together they target the wind-down side of sleep, helping quiet a busy mind so sleep can arrive on its own.

Magnesium is the most established of the three. A 2025 randomized, double-blind, placebo-controlled trial of magnesium bisglycinate in 155 adults with poor sleep found a modest but significant improvement in insomnia severity over four weeks, with the largest benefit in people who started with lower magnesium intake.

Citation: Schuster J, et al. Magnesium Bisglycinate Supplementation in Healthy Adults Reporting Poor Sleep: A Randomized, Placebo-Controlled Trial. Nature and Science of Sleep, 2025. PubMed Central: PMC12412596

L-theanine, an amino acid from tea, is the relaxation piece. A 2025 systematic review and meta-analysis found that its clearest effects are on subjective sleep quality and the sense of winding down, generally without daytime sedation.

Citation: Bulman A, et al. The effects of L-theanine consumption on sleep outcomes: A systematic review and meta-analysis. Sleep Medicine Reviews, 2025. DOI: 10.1016/j.smrv.2025.102076

The logic of combining them is that each acts on a slightly different part of the calming system, so a low, sensible dose of each can do more together than a large dose of any one alone. You can read the full breakdown of how these three ingredients work as a unit in our guide to the three-ingredient sleep stack.

Where Lunia fits

Lunia Restore was built around this calming pathway rather than around melatonin. It pairs Magnesium Bisglycinate (500 mg) and L-Theanine (300 mg), the two ingredients with the most human evidence, with 50 mg of Apigenin as the chamomile-derived layer for relaxation. The formula is melatonin-free, which means it supports the body's own wind-down rather than dosing a hormone that can leave some people groggy. We are also transparent about the science: Lunia Restore has not been through a finished-product clinical trial, so the case for it rests on the ingredient-level research laid out above, including the honest limits of that research. If you want a melatonin-free option that takes the apigenin evidence seriously without overselling it, that is the gap Lunia is designed to fill.

Learn more about Lunia Restore

Frequently Asked Questions

What is apigenin and what does it do?

Apigenin is a plant flavone (a type of flavonoid) found in chamomile, parsley, and celery. In the body it appears to act at the GABA-A receptor, the brain's main calming system, which is associated with relaxation and an easier transition toward sleep. It is also studied in aging research for its ability to inhibit an NAD+-consuming enzyme called CD38, though that work is preclinical.

How does apigenin compare to chamomile tea?

Apigenin is the calming compound inside chamomile, so chamomile tea delivers it, just in a small amount alongside many other plant compounds. A supplement that uses isolated apigenin provides a more consistent, measured dose than a cup of tea, where the apigenin content varies with the brew. Most of the human sleep research has actually been done on chamomile extract rather than isolated apigenin.

Why is apigenin linked to longevity?

Apigenin inhibits CD38, one of the main enzymes that consumes NAD+, a molecule tied to cellular energy and repair that declines with age. In cells and animals this raised NAD+ levels and produced longevity signals such as longer lifespan in worms and flies. Those findings are promising biology, but no human study has shown that apigenin supplements raise NAD+ or extend lifespan in people.

What is the right dose of apigenin?

There is no clinically proven apigenin dose for sleep in humans, because the human trials used chamomile extract rather than measured apigenin. In supplements it commonly appears at around 50 mg per serving, which is the amount in Lunia Restore. Because oral apigenin is poorly absorbed, taking very large amounts is not a reliable way to get a bigger effect.

Is apigenin safe for nightly use?

Apigenin is a common dietary compound with a long history of safe consumption and low reported toxicity, and chamomile extract has been well tolerated in human trials lasting many months. Reasonable cautions include allergy to ragweed or daisy-family plants, combining it with other sedatives or alcohol, blood-thinning medication, and pregnancy or breastfeeding, where data is limited. Check with your clinician if any of these apply to you.

Why is apigenin trending in the health space?

Two things drove the attention. Longevity-focused podcasts highlighted apigenin's NAD+ and CD38 mechanism, and a 2024 scientific review brought the sleep and aging research together in one place. The interest is real and the mechanism is genuinely interesting, but most of the buzz is built on preclinical findings rather than human outcome trials.

Should I take apigenin alone or in a stack?

A stack generally makes more sense. Apigenin's evidence as a standalone human sleep aid is thin, so it is usually paired with ingredients that have stronger human data, such as magnesium and L-theanine. Each works on a slightly different part of the calming system, so modest doses combined tend to be more useful than a large dose of apigenin by itself.

The bottom line

Apigenin is a real, well-characterized calming compound with a believable mechanism and a fascinating second life in aging research. The fair way to hold it is with both interest and restraint. The human sleep evidence is mostly about chamomile, and it is modest and mixed. The longevity story is mechanistically rich but entirely preclinical so far. At a sensible dose like 50 mg, taken alongside ingredients with stronger human support such as magnesium and L-theanine, apigenin earns a place in a calming sleep stack as the chamomile-derived layer. It does not earn a place as a miracle molecule, and anyone selling it that way is outrunning the science.

References

1. Viola H, Wasowski C, Levi de Stein M, Wolfman C, Silveira R, Dajas F, Medina JH, Paladini AC. Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects. Planta Medica. 1995;61(3):213-216. PubMed: 7617761
2. Kramer DJ, Johnson AA. Apigenin: a natural molecule at the intersection of sleep and aging. Frontiers in Nutrition. 2024;11:1359176. PubMed Central: PMC10929570
3. Kazemi A, Shojaei-Zarghani S, Eskandarzadeh P, Hashempur MH. Effects of chamomile (Matricaria chamomilla L.) on sleep: A systematic review and meta-analysis of clinical trials. Complementary Therapies in Medicine. 2024;84:103071. PubMed: 39106912
4. Zick SM, Wright BD, Sen A, Arnedt JT. Preliminary examination of the efficacy and safety of a standardized chamomile extract for chronic primary insomnia: a randomized placebo-controlled pilot study. BMC Complementary and Alternative Medicine. 2011;11:78. PubMed: 21939549
5. Abdullahzadeh M, Matourypour P, Naji SA. Investigation effect of oral chamomilla on sleep quality in elderly people in Isfahan: A randomized control trial. Journal of Education and Health Promotion. 2017;6:53. PubMed: 28616420
6. Escande C, Nin V, Price NL, Capellini V, Gomes AP, Barbosa MT, O'Neil L, White TA, Sinclair DA, Chini EN. Flavonoid apigenin is an inhibitor of the NAD+ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes. 2013;62(4):1084-1093. PubMed: 23172919
7. Tang D, Chen K, Huang L, Li J. Pharmacokinetic properties and drug interactions of apigenin, a natural flavone. Expert Opinion on Drug Metabolism and Toxicology. 2017;13(3):323-330. DOI: 10.1080/17425255.2017.1251903
8. Mao JJ, Xie SX, Keefe JR, Soeller I, Li QS, Amsterdam JD. Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial. Phytomedicine. 2016;23(14):1735-1742. PubMed: 27912875
9. Schuster J, Cycelskij I, Lopresti A, Hahn A. Magnesium Bisglycinate Supplementation in Healthy Adults Reporting Poor Sleep: A Randomized, Placebo-Controlled Trial. Nature and Science of Sleep. 2025;17:2027-2040. PubMed Central: PMC12412596
10. Bulman A, et al. The effects of L-theanine consumption on sleep outcomes: A systematic review and meta-analysis. Sleep Medicine Reviews. 2025;102076. DOI: 10.1016/j.smrv.2025.102076

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.